Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus-systematic review and meta-analysis

Molecular Nutrition and Food Research

Volumn 59, Issue 1, 2015, Pages 147-159

  Hausenblas, Heather A ^a   Schoulda, Jennifer A ^b   Smoliga, James M ^b  

^a JACKSONVILLE UNIVERSITY   (United States)

^b HIGH POINT UNIVERSITY   (United States)

Author keywords

Cardiometabolic; French paradox; Nutraceutical; SIRT1; Sirtuin

Indexed keywords

ANIMALIA;

CREATININE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; STILBENE DERIVATIVE; TRIACYLGLYCEROL;

BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIET SUPPLEMENTATION; DRUG EFFECTS; FACTUAL DATABASE; HUMAN; META ANALYSIS; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STILBENES; TRIGLYCERIDES;

EID: 84921033588     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400173     Document Type: Review

References (53)

1. Shaw, J. E., Sicree, R. A., Zimmet, P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87, 4-14.
2. Tahrani, A. A., Bailey, C. J., Del Prato, S., Barnett, A. H., Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378, 182-197.
3. Kume, S., Thomas, M. C., Koya, D., Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012, 61, 23-29.
4. Chalkiadaki, A., Guarente, L., Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat. Rev. Endocrinol. 2012, 8, 287-296.
5. Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G. et al., Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discov. 2012, 11, 443-461.
6. Mercken, E. M., Carboneau, B. A., Krzysik-Walker, S. M., de Cabo, R., Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res. Rev. 2012, 11, 390-398.
7. Zhou, G., Myers, R., Li, Y., Chen, Y. et al., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108, 1167-1174.
8. Zheng, Z., Chen, H., Li, J., Li, T. et al., Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2013, 61, 217-228.
9. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W. et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
10. Park, S. J., Ahmad, F., Philp, A., Baar, K. et al., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148, 421-433.
11. Baur, J. A., Sinclair, D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506.
12. Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P. et al., Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712-716.
13. Burgess, T. A., Robich, M. P., Chu, L. M., Bianchi, C. et al., Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch. Surg. 2011, 146, 556-564.
14. Marchal, J., Blanc, S., Epelbaum, J., Aujard, F. et al., Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS One 2012, 7, e34289.
15. Fiori, J. L., Shin, Y. K., Kim, W., Krzysik-Walker, S. M. et al., Resveratrol prevents beta-cell dedifferentiation in non-human primates given a high fat/high sugar diet. Diabetes 2013, 62, 3500-3513.
16. Bruckbauer, A., Zemel, M. B., Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab. Syndr. Obes. 2013, 6, 93-102.
17. Smoliga, J. M., Baur, J. A., Hausenblas, H. A., Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55, 1129-1141.
18. Smoliga, J. M., Colombo, E. S., Campen, M. J., A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging 2013, 5, 495-506.
19. Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C. et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339, b2700.
20. Rosenthal, R., Writing meta-analytic reviews. Psychol. Bull. 1995, 118, 1173-1181.
21. Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C. et al., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 1996, 17, 1-12.
22. Tricco, A. C., Ivers, N. M., Grimshaw, J. M., Moher, D. et al., Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet 2012, 379, 2252-2261.
23. Higgins, J. P., Thompson, S. G., Deeks, J. J., Altman, D. G., Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557-560.
24. Hedges, L. V., Olkin, I., Statistical Methods for Meta-Analysis, Academic Press, Orlando, FL 1985.
25. Wade, N., New York Times, New York 2012.
26. Bhatt, J. K., Thomas, S., Nanjan, M. J., Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32, 537-541.
27. Kumar, B. J., Joghee, N. M., Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int. Res. J. Pharm. 2013, 4, 245-249.
28. Elliott, P., Walpole, S., Morelli, L., Lambert, P. et al., Resveratrol/SRT-501. Drugs Future 2009, 34, 291-295.
29. Tome-Carneiro, J., Larrosa, M., Yanez-Gascon, M. J., Davalos, A. et al., One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013, 72, 69-82.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837-853.
31. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R. et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321, 405-412.
32. Vakkilainen, J., Steiner, G., Ansquer, J. C., Aubin, F. et al., Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107, 1733-1737.
33. Ritz, E., Orth, S. R., Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999, 341, 1127-1133.
34. Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W. et al., Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63, 225-232.
35. Ravid, M., Brosh, D., Ravid-Safran, D., Levy, Z. et al., Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Int. Med. 1998, 158, 998-1004.
36. Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I. et al., Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006, 55, 1832-1839.
37. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G. et al., Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91, 1590-1597.
38. Wong, R. H., Howe, P. R., Buckley, J. D., Coates, A. M. et al., Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 851-856.
39. Fryer, L. G., Parbu-Patel, A., Carling, D., The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 2002, 277, 25226-25232.
40. Ansari, K. A., Vavia, P. R., Trotta, F., Cavalli, R., Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSci. 2011, 12, 279-286.
41. Sanna, V., Roggio, A. M., Siliani, S., Piccinini, M. et al., Development of novel cationic chitosan and anionic alginate-coated poly(D, L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int. J. Nanomed. 2012, 7, 5501-5516.
42. Smoliga, J. M., Vang, O., Baur, J. A., Challenges of translating basic research into therapeutics: resveratrol as an example. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 158-167.
43. Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemoprotective agent. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1246-1252.
44. Popat, R., Plesner, T., Davies, F., Cook, G. et al., A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 2013, 160, 714-717.
45. Goldschmidt, H., Lannert, H., Bommer, J., Ho, A. D., Multiple myeloma and renal failure. Nephrol. Dial. Transplant. 2000, 15, 301-304.
46. Brasnyo, P., Molnar, G. A., Mohas, M., Marko, L. et al., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106, 383-389.
47. Goh, K. P., Lee, H. Y., Lau, D. P., Supaat, W. et al., Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int. J. Sport Nutr. Exerc. Metab. 2014, 24, 2-13.
48. Movahed, A., Nabipour, I., Lieben Louis, X., Thandapilly, S. J. et al., Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement. Altern. Med. 2013, 2013, 851267.
49. Frame, A. A., Kluge, M. A., Shenouda, S. M., Hartman, M.-L. et al., in Proceedings of the Society for Vascular Medicine 2011, Boston, MA, p. 229.
50. O'Connor, A. B., Building comparative efficacy and tolerability into the FDA approval process. J. Am. Med. Assoc. 2010, 303, 979-980.
51. Boule, N. G., Haddad, E., Kenny, G. P., Wells, G. A. et al., Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. J. Am. Med. Assoc. 2001, 286, 1218-1227.
52. Nolan, C. J., Damm, P., Prentki, M., Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378, 169-181.
53. Bashmakov, Y. K., Assaad-Khalil, S. H., Abou Seif, M., Udumyan, R. et al., Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014, 2014, 816307.